Bisphosphonate and Anastrozole trial - Bone Maintenance Algorithm Assessment

Phase 3

Active, not recruiting

• Conditions: Breast Cancer; Cancer - Breast

• Registration Number: ACTRN12605000003673
• Lead Sponsor: Barwon Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-07-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

Postmenopausal women- Adequately diagnosed and treated Stage I-IIIa early breast cancer- Oestrogen receptor and/or progesterone receptor positive breast cancer- Anastrozole is clinically indicated to be the best adjuvant strategy

Exclusion Criteria

Clinical or radiological evidence of distant spread- prior treatment with bisphosphonates within the past 12 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in lumbar vertebra and femoral neck BMD T-score after 5 years of anastrozole treatment[After 5 years of anastrozole treatment]

Secondary Outcome Measures

Name	Time	Method
Percent change in the lumbar vertebrae[Annually for 5 years];Biochemical markers[6 months after commencing alendronate];Evaluate the Osteoporosis Australia strategy for bone protection for this patient group.[At 5 years]